Connect with us

News

Digital health start-up raises US$3.7m for its outcomes-oriented fertility solution

Published

on

The digital health platform Conceive is on a mission to transform fertility after announcing the launch of its public beta. 

Conceive aims to improve health outcomes by helping people become pregnant faster, reduce costs, and uncover diagnoses. The company’s launch is fueled by a $3.7m seed round led by Kindred Ventures, with participation from Founder Collective, Great Oaks and over 40 founders and angels.

The start-up, currently offering services in the US, is an outcomes-based health platform that combines three elements — cohort-based community, evidence-based education, and 1:1 coaching — into a holistic program that helps members navigate and accelerate their fertility journey.

Figures show that one in six struggle to conceive and while early education emphasises avoiding pregnancy at all costs, the reality is that there is only a 22 per cent chance of conception per month in one’s 20s. “While infertility impacts men and women at the same rates, it is treated as existential for women and more of an afterthought for men,” says Lauren Berson, founder and CEO.

“Current solutions aren’t solving the problem, as they follow a one-size-fits-all, woman-focused playbook for a health challenge that involves two patients and is highly personalised,” Berson adds. “This results in a haphazard and difficult-to-navigate journey, with the potential for common causes of infertility to go undiagnosed, that may add to the mental, physical, and financial trauma.”

Conceive recently concluded an initial closed beta in which 54 per cent of members became pregnant, 36 per cent uncovered new diagnoses and 90 per cent felt supported in their journey.

Applications to join the public beta are now open nationwide. Members who join Conceive have to complete an onboarding questionnaire that helps to match them with the best peer group for their needs.

They meet once a week for 60-minute sessions, with access to their peer group and 1:1 coaching throughout the journey and they also get access to evidence-based resources to accelerate their paths to building a family. The program available in the US is eight weeks long and costs $549 with the possibility of scholarships for those unable to afford it.

Fertility is one of the few health areas that touches the entire population,” admits lead investor Kanyi Maqubela, managing partner of Kindred Ventures. “The clinical research is so young and underfunded and consumer experiences are sorely lacking.

“For such an idiosyncratic pathology, there is still no great personalisation in this market. With the right leader, this is as important and big an opportunity as I have ever seen and I think Lauren is that leader.”

Hunter Williamson Stitzer, Conceive’s head of clinical operations, points out that: “The average patient at a fertility clinic visits many specialists while navigating a very tricky journey.

“Isolation and loneliness often sends women and men into the Dr. Google ‘rabbit hole,’ which is exactly what we are all trying to avoid. Patients need trusted resources, access to experts, and a safe community during this isolating time. Conceive provides all of this and is a great complement to the care we can provide in-clinic.”

Later this year, Conceive also plans to launch additional fertility offerings for men, LGBTQ+ partners, and patients pursuing egg freezing.

For more information, visit weconceive.com.

Hormonal health

Toxins and climate harms having ‘alarming’ effect on fertility, research warns

Published

on

Simultaneous exposure to toxic chemicals and climate-related heat may be worsening fertility harms across humans and wildlife, research suggests.

The review of scientific literature looks at how endocrine-disrupting chemicals, often found in plastic, together with climate-related effects such as heat stress, are each linked to lower fertility and fecundity, meaning the ability to reproduce, across species including humans, wildlife and invertebrates.

Though the reproductive harms of each issue in isolation are well studied, there is little research on what happens when living organisms are exposed to both.

“Together, the two issues are likely to pose a greater threat to fertility, and the additive effect is “alarming”, said Susanne Brander, a study lead author and courtesy faculty at Oregon State University.

“You’re not just getting exposed to one, but two, stressors at the same time that both may affect your fertility, and in turn the overall impact is going to be a bit worse,” Brander said.

The paper looked at 177 studies.

Shanna Swan, a co-author on the new paper, co-produced a 2017 study that found sperm levels among men in western countries had fallen by more than 50 per cent over four decades. Other research has suggested human fertility has been declining at a similar rate.

The University of Washington’s Institute for Health Metrics and Evaluation has previously said the world was approaching a “low-fertility future”, with more than three quarters of countries below replacement rate by 2050.

The new paper’s authors focused on the effects of endocrine-disrupting chemicals and substances, including microplastics, bisphenol, phthalates and PFAS.

These are thought to cause a range of serious reproductive problems, disrupt hormones and be a potential driver of falling fertility.

Brander said the harms linked to these chemicals are often similar across organisms, from invertebrates to humans.

Phthalates, for example, have been linked to altered sperm shape in invertebrates, spermatogenesis in rodents, meaning sperm production, and reduced sperm counts in humans.

PFAS are also thought to affect sperm quality, and both have been linked to hormone disruption.

The chemicals are widespread in consumer goods, so people are often regularly exposed.

Meanwhile, previous research has shown how rising temperatures, lower oxygen levels and heat stress, among other effects linked to climate change, may also worsen infertility.

Heat stress has been found to affect human hormones, and is linked to spermatogenesis in rodents and bulls.

Research shows temperature also plays a role in sex determination in fish, reptiles and amphibians.

The species has evolved to choose which sex it produces in part based on temperature, and the heating planet can “push it too far in one direction or the other, which overrides that evolutionary benefit”, Brander said.

Similarly, many endocrine disruptors may alter environmental sex determination.

The study set out some of the overlapping effects of chemical exposure and climate change across taxonomic groups, from invertebrates to humans.

In birds, for example, exposure to increased temperature, PFAS, organochlorines and pyrethroids may each individually cause abnormal sperm, increased fledgling mortality, abnormal testes and population decline.

“What happens if they’re exposed to more than one of those stressors at the same time? There has been little exploration of that question.

“Even if there have not been a lot of studies looking at these simultaneously, if you have two different factors that both cause the same adverse effect, then there’s a likelihood that they are going to be additive,” Brander said.

Katie Pelch, a senior scientist with the Natural Resources Defense Council nonprofit, who was not part of the study, said the authors had reviewed high-quality science.

She said she wanted to see more examples of the overlap in impacts, but agreed with the overall premise.

“It is likely [multiple stressors] would have an additive effect, at very least, even if they have different mechanisms of harm,” Pelch added.

The solution to the systemic problems would involve tackling climate change and reducing the use of toxic chemicals.

The study cites the global reduction in the use of DDT and PCBs achieved under the Stockholm Convention as an example of an effective measure, but Brander said much more is needed.

“There is enough evidence in both areas to act to reduce our impact on the planet,” she said.

Continue Reading

Pregnancy

Home blood pressure checks could lower heart risks for new mothers – study

Published

on

Home blood pressure checks after hypertensive pregnancy could cut the risk of heart attack, stroke and potentially early death, research suggests.

Women who regularly monitored their blood pressure in the weeks after giving birth, and had doctors tailor their medication if needed, had better functioning arteries nine months later than those who received routine care.

When the medication was adjusted to account for blood pressure changes, the women ended up with less stiff arteries, an effect researchers estimated could reduce the future risk of heart attack or stroke by 10 per cent.

Paul Leeson, professor of cardiovascular medicine who led the study, said the findings suggested that the weeks after birth provided a “powerful and often overlooked opportunity” to protect women’s future health.

“By simply monitoring blood pressure at home, new mothers with hypertensive pregnancies can protect their bodies from future damage,” he said.

High blood pressure, in the form of gestational hypertension or pre-eclampsia, where there are signs of organ damage, affects 5 to 10 per cent of pregnant women.

The condition can damage the mother’s organs and endanger the baby’s life.

Beyond the immediate threat to mother and baby, hypertension in pregnancy can raise the risk of long-term problems, with women three times more likely to develop high blood pressure and twice as likely to have heart disease later in life.

The Oxford team recruited 220 women who developed hypertension in pregnancy. All were on blood pressure medication but were due to reduce their dosage and eventually stop taking the drugs.

In the study, 108 women had standard care in which their medication was reduced based on a few blood pressure checks in the eight weeks after giving birth.

The remaining 112 women used a monitor to check their blood pressure at home each day.

They entered the readings into an app shared with doctors who, if needed, changed their medication day to day, with the aim of giving them better control of their blood pressure.

The new approach led to much better control of the women’s blood pressure, and in tests six to nine months later the women had less stiff arteries.

Stiff arteries are less effective at expanding and contracting, which can drive high blood pressure and ultimately the formation of clots that can block blood vessels and cause heart attacks and strokes.

Trials are now under way to find effective ways of rolling out blood pressure monitoring to women after hypertensive pregnancies. One option is for specialist NHS clinics to deliver the care.

Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which funded the work, said the results highlighted a crucial window after birth when paying close attention to blood pressure could help protect women’s heart health for years to come.

“We now look forward to seeing results from larger studies with longer follow-up to see how this might save women’s lives,” she said.

Continue Reading

Fertility

Researcher explores weight loss jab impact on PCOS

Published

on

Weight loss jabs are being studied to see if they could help women with polycystic ovary syndrome (PCOS)

The condition, which affects up to one in ten women, changes how the ovaries work and is linked to infertility and weight gain.

Dr Shagaf Bakour has won a £60,000 NHS research grant through Sandwell and West Birmingham NHS Trust to look at whether drugs such as Mounjaro and Ozempic might help.

“The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked,” she said.

Women with PCOS have higher levels of male hormones and can suffer from irregular periods and symptoms such as excess body or facial hair, the NHS said.

Associated weight gain can also lead to an increased risk of diabetes and heart problems.

Bakour, a gynaecologist and director of medical education at Aston Medical School, will work with a team to evaluate the effect of the weight loss medicines on metabolic and reproductive outcomes.

The drugs mimic a hormone called GLP-1, which suppresses appetite.

Bakour, alongside Dr Hoda Harb, a consultant obstetrician and gynaecologist at the NHS trust, will review existing evidence on their use and assess how they help patients with PCOS.

“The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care,” she said.

“The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways.

Prof Elizabeth Hughes, director of research and development at the NHS trust, said the effects of PCOS, including infertility, were “very emotive subjects”.

“We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition,” she added.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.